Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: An open-label study

David G. Vossler, Joan A. Conry, Jerome V. Murphy, Rose Mary Boustany, Stella Legarda, Kevin Ruggles, Steven Schachter, Kaackuzhali Krishnamurthy, Raj Sheth, Blanca Vazquez, Greg Barkley, Harry Chugani, Michael Duchowny, Robert Flamini, Joseph Sirven, Basim Uthman, James Wheless, Jorge Asconape, C. Steve Miller, John PellockCohn Van Orman, Francis Filloux

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Purpose. To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open-label setting. Methods. Thirty patients with refractory PME (aged ≥ 5 years), who were taking up to three antiepileptic drugs, received adjunctive zonisamide (≤ 6 mg/kg/day) therapy for 16 weeks. Myoclonic seizures were recorded daily over a 24-hour period or in 10-minute epochs in the morning, afternoon, and evening. Safety was assessed via adverse events (AEs); efficacy was measured by the percentage of patients experiencing a ≥ 50% decrease in myoclonic seizure frequency from baseline. Results. Treatment-related AEs, experienced by 53% (n = 16/30) of patients, led to five patients discontinuing zonisamide. The most common AEs were decreased appetite, somnolence, and asthenia. Overall, 36% of patients (n = 10/28) had a ≥ 50% reduction in myoclonic seizure frequency. Conclusions. These results suggest that zonisamide may be useful in the treatment of patients with PME. However, due to the size and open-label character of this study, further research is required.

Original languageEnglish (US)
Pages (from-to)31-34
Number of pages4
JournalEpileptic Disorders
Issue number1
StatePublished - Mar 2008


  • Antiepileptic drug
  • Myoclonic seizures
  • Progressive myoclonic epilepsy
  • Zonisamide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: An open-label study'. Together they form a unique fingerprint.

Cite this